Researcher:
Yeşiltepe Mutlu, Rahime Gül

Profile Picture
ORCID

Job Title

Faculty Member

First Name

Rahime Gül

Last Name

Yeşiltepe Mutlu

Name

Name Variants

Yeşiltepe Mutlu, Rahime Gül

Email Address

Birth Date

Filters

2017 - 2019162020 - 202329

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.8a332a11-03d9-4fa0-85c9-ea2c15c7aa33

Search Results

Now showing 1 - 10 of 45
  • Placeholder
    PublicationMetadata only
    I'm not alone-my take-away message from the my friend diabetes camp
    (Springernature, 2020) N/A; N/A; Yeşiltepe Mutlu, Rahime Gül; Gökçe, Tuğba; Can, Ecem; Muradoğlu, Serra Küpçüoğlu; Hatun, Şükrü; Faculty Member; Doctor; Nurse; Doctor; Faculty Member; School of Medicine; N/A; N/A; N/A; School of Medicine; N/A; Koç University Hospital; Koç University Hospital; Koç University Hospital; N/A; 153511; N/A; N/A; N/A; 153504
    N/A
  • Placeholder
    PublicationMetadata only
    A rare cause of chronic hyponatremia in an infant: aldosterone synthase type-2 deficiency
    (Springer, 2018) Güran, Tülay; Yeşiltepe Mutlu, Rahime Gül; Taşdemir, Mehmet; Kızılkan, Nuray Uslu; Börklü Yücel, Esra; Hatun, Şükrü; Kayserili, Hülya; Bilge, İlmay; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 153511; N/A; 221274; N/A; 153504; 7945; 198907
    N/A
  • Placeholder
    PublicationMetadata only
    Management of rapidly progressive precocious puberty in a patient with mosaic turner syndrome
    (Societatea Romana de Endocrinologie, 2021) Ozcabi, B.; Kirmizibekmez, H.; Dursun, F.; Guran, T.; Yeşiltepe Mutlu, Rahime Gül; Faculty Member; School of Medicine; 153511
    Context: Rapidly progressive precocious puberty (RPPP) is a rare condition in Turner syndrome (TS), with no consensus on treatment and follow-up. Only 12 cases have been reported so far. Objective: We aimed to evaluate the effects of the GnRH analog (GnRHa) on growth and anti-mullerian hormone (AMH) levels in TS and RPPP. Design. The clinical and laboratory data was recorded at baseline and after treatment. Subjects and Methods: An 8.1-year old girl with a karyotype of 45, X/46, XX presented with breast development at Tanner stage-2. Breast development advanced to Tanner stage-3 at the age of 8.7 years. Growth velocity (GV) was 8 cm/year. Bone age was 11 years with a predicted adult height of 152 cm. Luteinizing hormone (LH) was 1.69mIU/mL and estradiol was 33pg/mL, confirming the central puberty. AMH level was 6.33ng/mL. The sizes of ovaries and uterus were compatible with the pubertal stage, with an endometrial thickness of 5 mm. GnRHa was started for RPPP. Results: After three months, GV declined to 0 cm/3 months and AMH level to 50% of the baseline. Growth hormone (GH) treatment was started for insufficient growth. GV improved with GH treatment, as well as a far more decreased AMH level. Conclusion. GV usually declines before puberty in patients with TS, even if the mid-parental height is tall. RPPP should be considered if GV is increased. Excessive suppression of growth may be prevented with GH treatment. GnRHa treatment also plays a role in reducing AMH levels in patients with TS.
  • Placeholder
    PublicationMetadata only
    Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
    (Endocrinology Research Centre, 2018) Dovc, Klemen; Philippov, Yury I.; Laptev, Dmitry N.; Patrakeeva, Evgenia M.; Chernilova, Lubov O.; Zalevskaya, Alsu G.; Shestakova, Marina V.; Battelino, Tadej; Yeşiltepe Mutlu, Rahime Gül; Faculty Member; School of Medicine; 153511
    Backgraund: A closed-loop glucose control system or 'artificial pancreas' consists of three components - a Continuous Glucose Monitor (CGM), infusion pumps to deliver hormone(s) and a sophisticated dosing algorithm to control hormone delivery. In the past years, numerous studies with closed-loop system devices were conducted with gradual shift to out-of-hospital environment and with lengthening study duration. AIMS: To compare efficacy and safety of closed-loop insulin pump use in children with type 1 diabetes mellitus in compare with conventional insulin treatment (continuous subcutaneous insulin infusion (CSII) with our without CGM) based on randomized control trials data (RCT). Methods: In the systematic review we have include 28 randomized controlled trials results indexed in PubMed, Medline databases published till 15 June 2017. The efficacy on metabolic control in this study evaluated by the proportion of time within target range (preferably 70 to 180 mg/dl if reported) and mean (median) glucose based on sensor measurements, and the safety evaluated by time in hypoglycemia (below 70 mg/dl if reported). Results: Increased time in range in the night period was observed in all RCT. Only 3 RCT showed decrease of the time in range within 24 h evaluation period. In one RCT the significant positive differences have been shown in the time in range for dual hormone closed-loop glucose control system in compare with insulin-only artificial pancreas. Mean glycaemia and glucose variability changes were not in the same manner in different RCT, both in the night only and in 24 h estimation period. Night hypoglycemia duration decreased in most RCT with closed-loop control in compare with CSII, and increased only in 2 RCT. When all-day estimation period the time in hypoglycemia changed not in the same manner in different RCT. Valuable methodology differences of the glycaemic control estimation within observed RCT brought significant complications in the data analysis and made impossible the results quantitative estimation to prepare a metaanalysis. Conclusions: Much work has been done to develop effective and safe artificial pancreas, but not all RCTs confirmed advantages of closed-loop glucose control in compare with CSII in children and adolescents in real life. More research with prospective randomized control design required to prove benefits of closed-loop glucose control. Further RCTs should have an uniform methodology for glycemic control assessment and long duration that will allow to use cumulative measures in a closed-loop efficacy estimation (HbA(1c)).
  • Placeholder
    PublicationMetadata only
    A short-term evaluation of children with diabetes using medtronic 780g system- a single center experience from Turkey
    (Mary Ann Liebert, Inc, 2022) N/A; N/A; Yeşiltepe Mutlu, Rahime Gül; Eviz, Elif; Can, Ecem; Gökçe, Tuğba; Muradoğlu, Serra Küpçüoğlu; Hatun, Şükrü; Faculty Member; Researcher; Nurse; Doctor; Doctor; Faculty Member; School of Medicine; School of Medicine; N/A; N/A; N/A; School of Medicine; N/A; N/A; Koç University Hospital; Koç University Hospital; Koç University Hospital; N/A; 153511; 327618; N/A; N/A; N/A; 153504
    N/A
  • Placeholder
    PublicationMetadata only
    Faster compared with standard insulin aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: a double-blind randomized crossover trial
    (American Diabetes Association (ADA), 2020) Dovc, Klemen; Piona, Claudia; Bratina, Natasa; Bizjan, Barbara Jenko; Lepej, Dusanka; Nimri, Revital; Atlas, Eran; Muller, Ido; Kordonouri, Olga; Biester, Torben; Danne, Thomas; Phillip, Moshe; Battelino, Tadej; N/A; Yeşiltepe Mutlu, Rahime Gül; Faculty Member; School of Medicine; Koç University Hospital; 153511
    Objective We evaluated the safety and efficacy of day-and-night fully closed-loop insulin therapy using faster (Faster-CL) compared with standard insulin aspart (Standard-CL) in young adults with type 1 diabetes.Research design and methods In a double-blind, randomized, crossover trial, 20 participants with type 1 diabetes on insulin pump therapy (11 females, aged 21.3 +/- 2.3 years, HbA(1c) 7.5 +/- 0.5% [58.5 +/- 5.5 mmol/mol]) underwent two 27-h inpatient periods with unannounced afternoon moderate-vigorous exercise and unannounced/uncovered meals. We compared Faster-CL and Standard-CL in random order. During both interventions, the fuzzy-logic control algorithm DreaMed GlucoSitter was used. Glucose sensor data were analyzed by intention-to-treat principle with the difference (between Faster-CL and Standard-CL) in proportion of time in range 70-180 mg/dL (TIR) over 27 h as the primary end point. Results The proportion of TIR was similar for both arms: 53.3% (83% overnight) in Faster-CL and 57.9% (88% overnight) in Standard-CL (P = 0.170). The proportion of time in hypoglycemia <70 mg/dL was 0.0% for both groups. Baseline-adjusted interstitial prandial glucose increments 1 h after meals were greater in Faster-CL compared with Standard-CL (P = 0.017). The gaps between measured plasma insulin and estimated insulin-on-board levels at the beginning, at the end, and 2 h after the exercise were smaller in the Standard-CL group (P = 0.029, P = 0.003, and P = 0.004, respectively). No severe adverse events occurred. Conclusion Fully closed-loop insulin delivery using either faster or standard insulin aspart was safe and efficient in achieving near-normal glucose concentrations outside postprandial periods. The closed-loop algorithm was better adjusted to the standard insulin aspart.
  • Placeholder
    PublicationMetadata only
    A possibly fatal outcome of oral contraceptive therapy: estrogen triggered hereditary angioedema attack in an adolescent
    (Galenos Yayınevi, 2021) Demirkol, Demet; Birben, Esra; Soyer, Özge; N/A; Balkancı, Uğur Berkay; Yeşiltepe Mutlu, Rahime Gül; Yılmaz, Özlem; Saçkesen, Cansın; Undergraduate Student; Faculty Member; Doctor; Faculty Member; School of Medicine; School of Medicine; N/A; School of Medicine; Koç University Hospital; Koc University Hospital; N/A; 153511; 140706; 182537
    Hereditary angioedema (HAE) is characterized by recurrent angioedema attacks with no urticaria. This disease has a high mortality due to asphyxia. Level of complement 4 (C4), C1 esterase inhibitor (C1-INH) level and function, and genetic mutations determine different endotypes of HAE. Clinical presentation and the triggers of vasogenic edema may change according to the endotypes. An adolescent girl with oligomenorrhea, obesity, hirsutism, and acanthosis nigricans was diagnosed with polycystic ovary syndrome (PCOS) and prescribed ethinyl estradiol & cyproterone acetate containing oral contraceptive (OC). On the 16th day of treatment, she developed angioedema on the face, neck, and chest leading to dyspnea. Adrenaline, antihistamine, and corticosteroid treatments were ineffective. In the family history, the patient's mother and two cousins had angioedema attacks. C1-INH concentrate was administered with a diagnosis of HAE. C4, and C1-INH level and activity were normal. Genetic analysis identified a mutation of Factor XII (F12) gene, and the diagnosis of Factor 12 (F12)-related HAE was made. OC treatment discontinued. She has had no additional angioedema attacks in the follow-up period of two years. OC containing estrogen may induce the life-threatening first attack of F12-related HAE even in children. Recurring angioedema attacks in the family should be asked before prescribing estrogen-containing OC pills.
  • Placeholder
    PublicationMetadata only
    The attitudes, experiences, and self-competencies of pediatric endocrinology fellows and attending physicians regarding diabetes technology: the Turkey experience
    (Walter De Gruyter Gmbh, 2022) Eren, Erdal; N/A; N/A; N/A; N/A; N/A; Yeşiltepe Mutlu, Rahime Gül; Eviz, Elif; Gökçe, Tuğba; Sakarya, Sibel; Hatun, Şükrü; Faculty Member; Researcher; Doctor; Faculty Member; Faculty Member; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; Koç University Hospital; 153511; 327618; N/A; 172028; 153504
    Background: Unlike in Western countries, the use of diabetes technologies has been limited in Turkey, or at least until the last few years. This low adoption frequency may be attributed to the lack of experience of pediatric diabetes teams in working with new technologies. The aim of this study is to evaluate the attitudes, experiences and self-efficacies of pediatric endocrinology fellows and attending physicians in terms of use of continuous subcutaneous insulin infusion (CSII) therapy and continuous glucose monitoring (CGM) systems. Methods: The questionnaire used in this study consisted of 63 questions including 10 questions evaluating the demographic characteristics and experience of the participants, 33 Likert-type questions related to self-competency, 17 yes/no questions and 3 open-ended questions which evaluated attitudes towards our study area. This questionnaire was e-mailed to pediatric endocrinology fellows and attending physicians working in Turkey. Results: A total of 24 fellows and 28 attending physicians working in the field of pediatric endocrinology participated in the survey. Of the respondents, 61% reported that there was no formal training curriculum regarding diabetes technology at their institutions. The mean scores obtained from the Likert scale questions measuring self-competency in using CSII and CGM were 3.8 and 3.3 out of 5, respectively. Of the respondents, 55% judged themselves to be under-skilled in interpreting pump reports while 39% of the respondents reported themselves as being under-skilled in interpreting CGM reports. Conclusions While it is true that training programs for using diabetes technology have been established by the National Pediatric Endocrinology Association in Turkey, the development of a specific curriculum for institutions that provide pediatric endocrinology fellowship training in this framework will increase the self-confidence of pediatric endocrinologists in this matter and this will ultimately contribute to the improvement of the metabolic control of children with diabetes.
  • Placeholder
    PublicationMetadata only
    The my friend diabetes carbohydrate bolus calculator: user experiences
    (Mary Ann Liebert, Inc, 2022) N/A; N/A; Karakuş, Kağan Ege; Gökçe, Tuğba; Can, Ecem; Muradoğlu, Serra Küpçüoğlu; Eviz, Elif; Yeşiltepe Mutlu, Rahime Gül; Hatun, Şükrü; Undergraduate Student; Doctor; Nurse; Doctor; N/A; Researcher; Faculty Member; Faculty Member; School of Medicine; N/A; N/A; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; N/A; N/A; N/A; 327618; 153511; 153504
    N/A
  • Placeholder
    PublicationMetadata only
    Bone age determination in girls with early puberty and limitations of adult height prediction: can automated evaluation (bonexpert (TM)) be a solution?
    (Karger, 2019) N/A; N/A; Yeşiltepe Mutlu, Rahime Gül; Çapacı, Merve; Uzunköprü, Gizem; Hatun, Şükrü; Faculty Member; Undergraduate Student; Undergraduate Student; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 153511; N/A; N/A; 153504
    N/A